Paragon Bioservices is expanding a new process development and cGMP manufacturing facility. Growing need for broad gene therapy manufacturing capacity from its current and future client base is driving the company’s investment in this new facility, which the company expects will include commercial manufacturing capabilities in 18 to 24 months.   The company currently provides full process and analytical development and cGMP clinical manufacturing services from its 80,000 square-foo...